Regenerative Medicine: The Milestones That Hold

Regenerative medicine has produced more announcements than durable results. That is not cynicism — it is the normal shape of a young field working on genuinely hard problems. What is worth doing periodically is separating the findings that held from the ones that did not.

What held

Haematopoietic transplantation. The first successful marrow transplants in the late 1960s established that transplanted stem cells could reconstitute an entire failed system in a human being. The 1988 cord blood transplant in a child with Fanconi anaemia extended that to perinatal sources and launched cord blood banking worldwide. Decades of follow-up have not undermined either result.

The ISCT minimal criteria. The 2006 definition of what qualifies as a mesenchymal stromal cell is not glamorous, and it may be the single most useful document the field produced. Before it, laboratories described incomparable populations by the same name.

Induced pluripotency. The 2006 reprogramming result was independently replicated almost immediately and has withstood every subsequent challenge.

The paracrine reframing. The accumulating observation that transplanted stromal cells exert benefit while engrafting poorly and persisting briefly redirected the field from replacement toward signalling — and made cell-free vesicle preparations a coherent therapeutic category rather than a workaround.

What did not

Early claims of broad transdifferentiation across germ layers largely dissolved under scrutiny, explained substantially by cell fusion and detection artefact. Several high-profile reprogramming claims were retracted outright. And the assumption that transplanted cells act principally by engrafting and replacing lost tissue has not survived contact with the evidence in most applications.

The corrections matter as much as the confirmations. A field that cannot retract cannot be trusted when it affirms.

Where the discipline actually stands

Three things are now settled enough to build on. Perinatal tissue is a superior and ethically uncomplicated source of primitive stromal populations. Paracrine signalling — including vesicle-mediated transfer — accounts for a substantial share of observed effect. And product characterisation is the rate-limiting variable: not the biology, but the ability to demonstrate consistently what is in the vial.

The honest summary

This is a field whose scientific foundation is stronger than its clinical translation, and whose translation is limited less by mechanism than by manufacturing discipline and evidentiary rigour. The work that will matter over the next decade is unglamorous — validated potency assays, standardised release criteria, adequately powered controlled trials, and honest reporting of results that do not confirm the hypothesis.

Preparations that arrive with a complete analytical record are participating in that correction. Preparations that arrive with a claim are not.